Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov092021	Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today Read All »	View HTML
Toggle SummaryJan082021	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummaryNov042021	Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 SAN DIEGO , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryMay132021	Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia 4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study Continued in Remission without Further Therapeutic Intervention at 6-month Follow-up 1 of 3 Read All »	View HTML
Toggle SummaryApr272021	Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight Interim Phase 1 Clinical Data from the Company’s FT516 and FT538 Programs for Relapsed / Refractory AML SAN DIEGO , April 27, 2021 (GLOBE NEWSWIRE) -- Fate Read All »	View HTML
Toggle SummaryAug192021	Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma 10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy 8 of 11 Patients in FT516 Multi-Dose Read All »	View HTML
Toggle SummaryOct012021	Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting SAN DIEGO , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Read All »	View HTML
Toggle SummaryJan062021	Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants SAN DIEGO , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All »	View HTML
Toggle SummaryJan042021	Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock SAN DIEGO , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has Read All »	View HTML
Toggle SummarySep152021	Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK Cells SAN DIEGO , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.